Department of Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
Sci Rep. 2024 Aug 27;14(1):19891. doi: 10.1038/s41598-024-69382-8.
Osteosarcoma is the most common primary bone malignancy in children and young adults, and it has few treatment options. As a result, there has been little improvement in survival outcomes in the past few decades. The need for models to test novel therapies is especially great in this disease since it is both rare and does not respond to most therapies. To address this, an NCI-funded consortium has characterized and utilized a panel of patient-derived xenograft models of osteosarcoma for drug testing. The exomes, transcriptomes, and copy number landscapes of these models have been presented previously. This study now adds whole genome sequencing and reverse-phase protein array profiling data, which can be correlated with drug testing results. In addition, four additional osteosarcoma models are described for use in the research community.
骨肉瘤是儿童和青少年中最常见的原发性骨恶性肿瘤，治疗选择有限。因此，在过去几十年中，生存结果几乎没有改善。由于这种疾病既罕见又对大多数治疗方法没有反应，因此非常需要模型来测试新的治疗方法。为了解决这个问题，一个由 NCI 资助的联盟已经对一组骨肉瘤患者来源的异种移植模型进行了特征描述和利用，用于药物测试。这些模型的外显子组、转录组和拷贝数图谱之前已经有报道。本研究现在增加了全基因组测序和反相蛋白芯片分析数据，可以与药物测试结果相关联。此外，还描述了另外四个骨肉瘤模型，供研究界使用。
